In women with BRCA2 mutations, ovarian cancer onset is an average of 8–10 years later, therefore risk-reducing surgery is delayed until age 40–45 years.22,24,25 In addition it is recommended to discuss with women of childbearing ages the option of stopping the chain of BRCA heritage with in vitro fertilization and preimplantation genetic testing.22 This evidence concerns the gene BRCA2 and ovarian carcinoma.